All research papers

Facilitating the mid-ventilation SABR lung technique with deformable image registration: retrospective study into contour accuracy.

Absolute Lymphocyte Counts in Patients with Advanced Lung Cancer Receiving Thoracic Radiotherapy and Immunotherapy:a retrospective case series

Radioactive Iodine Therapy Dosimetry for a Case of Functioning Follicular Thyroid Carcinoma Metastases

PSMA Therapy Grey Zones: Actinium, Lutetium, or Terbium for the Future of Radioligand therapy?

Synthesis and Characterization of Radio-Halogenated Talazoparib Analogues for Imaging and Radioligand Therapy.

Adult intraventricular meningiomas in contemporary neurosurgical practice: a systematic review and meta-analysis.

A Hybrid Perception Network for Accurate and Interpretable Brain Tumor Classification Using Multi-Modal Imaging.

External validation of dose to heart substructures and the association with non-cancer death after SBRT in stage I-II NSCLC patients.

Quantitative Imaging Evaluation of Structural and Densitometric Changes in Major Salivary Glands After 177Lu PSMA Radioligand Therapy.

Evaluation of [²²⁵Ac]Ac-PSMA-617 vis-a-vis Rechallenge [¹⁷⁷Lu]Lu-PSMA-617 PRLT Versus Cabazitaxel or Oral Metronomic Chemotherapy in mCRPC: An Observational Analysis of Outcome and Toxicity Profiles in a Real-World Clinical Scenario.

High-yield reactor production of terbium-161 using thin-layer gadolinium-160 targets, simplified chloride based separation and radiolabeling of DOTA based ligands.

Selective CXCR4-Targeting Radioconjugates Derived from LY2510924: Evaluation of [¹⁸F]AlF-NOTA-SC, [¹⁷⁷Lu]Lu-BL02, and [¹⁶¹Tb]Tb-BL02 for Theranostic Development.

Biologically adaptive radiotherapy for oropharyngeal Cancer (BARitOne): An R-IDEAL stage 2a-2b technical optimisation, feasibility, and safety study - Study protocol.

Early outcomes of online adaptive MR-guided SBRT for localized prostate cancer: a prospective study.

MRI-guided adaptive stereotactic body radiotherapy for the prostate bed: a prospective study of safety, tolerability, and patient-reported quality-of-life outcomes.

Dosimetric robustness of tumour- and fiducial-based tracking in Radixact lung stereotactic body radiotherapy: a four-dimensional CT-based simulation using imaging-derived tracking-error scenarios.

Bias and precision analysis in curve fitting for hyperthyroidism clinical dosimetry.

Evaluation of qualitative and quantitative PET parameters in primary prostate cancer patients: double-match comparison of 18F-flotufolastat- and 68Ga-PSMA-11-PET

177Lu-FAP-2286 Radioligand Therapy in End-Stage Metastatic Cancer: a promising theranostic approach

Active dosimeters used in interventional radiology and their response in pulsed radiation beams. Impact in clinical practice.

Partial Remission in Pediatric Relapsed Neuroblastoma After Multiple Cycle Low-Dose 211 At-MABG Therapy.

Tuberculosis Mimicking Tumor Progression on Dual-tracer 68Ga-DOTATATE and 18F-FDG PET/CT in Metastatic Neuroendocrine Tumor of Unknown Primary: A Potential Imaging Pitfall in Neuroendocrine Tumor Surveillance.

Bevacizumab plus iparomlimab/tuvonralimab with hepatic artery infusion chemotherapy followed by stereotactic body radiotherapy in patients with BCLC stage C hepatocellular carcinoma with thrombus and/or extrahepatic oligometastases (BITS-TO-HCC): study protocol of a prospective, single-center, single-arm, phase II study.

Clinical implementation of automated IMRT/VMAT planning for lung cancer radiation therapy using the expedited constrained hierarchical optimization (ECHO) system.

A dosimetric study of single-fraction stereotactic body radiotherapy using proton versus photon for spinal metastases.

Five-Year Patient-Reported Outcomes After SBRT for Prostate Cancer: A Benchmark for Radiotherapy, but How Far Across Modalities?

Evaluation of a novel abdominal compression airbag for respiratory motion management and setup reproducibility in upper abdominal radiotherapy.

Development and validation of a machine learning-based hierarchical classification model for predicting the early therapeutic response to initial ¹³¹I therapy in papillary thyroid carcinoma.

Phase I/IIa clinical trial of ⁶⁸Ga-PSMA-11 synthesized by a newly developed automated module using cyclotron-generated ⁶⁸Ga.

Not always a perfect match: discrepancies between PSMA PET/CT and MRI in prostate cancer diagnosis and staging.

Experimental and Computational Evaluation of Hybrid Bi₂O₃/WO₃ Nanoparticle-Filled Epoxy Composites for Lead-Free Tc-99m Gamma-Ray Shielding in Occupational Radiation Protection.

Development of an artificial intelligence driven dose prediction pipeline for online adaptive magnetic resonance-guided radiotherapy.

Prospective comparison of [⁶⁸Ga]Ga-FAPI-04 PET/MRI, [¹⁸F]FDG PET/CT, and contrast-enhanced MRI for predicting pathologic complete response after neoadjuvant chemotherapy in breast cancer.

Palladium-103 as a Theranostic Auger Electron Emitter: From Cyclotron Production to Preclinical SPECT Evaluation in Murine and Canine Models.

Dose Reconstruction After a WD‒XRF Spectrometer Accident Using Minute-Rate TLD Measurements.

Stereotactic Radiation Therapy for Lung Cancer Brain Metastases: Dose Optimization and Prognostic Prediction via Biologically Effective Dose-Based Empirical Dose-Response Modeling and Extreme Gradient Boosting-SHapley Additive Explanations Machine Learning.

Evaluation of professional practices in hospital radiopharmacy using a process-based clinical audit: a quality improvement study.

Dosimetry evaluation of an MRI guided small animal irradiator.

Focused ultrasound and stereotactic radiosurgery: a preliminary investigation of a novel, combined therapy for noninvasive neurosurgery.

Randomized phase II trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in patients with metastatic castration-resistant prostate cancer: the CheckPRO, CA209-8TY trial.

Re: Robert M. Meier, Nima Aghdam, Alan C. Beckman et al. 10-yr Survival and Toxicity Outcomes of Stereotactic Body Radiotherapy for Prostate Cancer: A Nonrandomized Clinical Trial. Eur Urol In press. http://dx.doi.org/10.1016/j.eururo.2026.04.029.

Dosimetric comparison between ring_gantry and c_arm modalities for lattice radiotherapy in large-volume tumors across different anatomical sites.

Evaluating Interim Progression: First Posttherapy ¹⁷⁷Lu-PSMA SPECT/CT Relative to Baseline PSMA PET/CT.

Evaluation of 9-Minute Dual-Energy Peak Time-Reduced 360° CZT Total-Body [¹⁷⁷Lu]Lu-PSMA SPECT/CT Imaging with Comparisons to [⁶⁸Ga]Ga-PSMA PET.

Clinical applications with expired EBT-XD radiochromic film in radiotherapy.

Deciphering the phenotypic responses to ¹⁷⁷Lu-based radioligand therapy to identify efficacious combinations.

Accelerating actinium-225 purification by high-pressure ion chromatography.

Influence of precursor purity on the low-dose TL and OSL response of flux-grown pure α-Al₂O₃.

Development of a ¹⁷⁷Lu-Labeled Glypican-3-Targeted Antibody Radiopharmaceutical for Adjuvant Radionuclide Therapy Following Hepatocellular Carcinoma Resection.

How to optimise prostate SBRT: ESTRO clinical practice consensus recommendations.

First Measurement: Proactively Sparing the Immune System During SBRT to Early-Stage Lung Cancer-A Randomized Phase II Study.

Precision Stereotactic Body Radiotherapy for Ultra-Central NSCLC: Tailored Margins Reduce Toxicity Without Compromising Tumor Control.

Imaging 131 I in mouse phantoms and living mice with the MACACO III+ Compton camera

Head-to-head comparison of 99mTc-MIP-1404 CZT SPECT/CT and ⁶⁸Ga/PSMA-11 PET/CT for primary staging of high-risk prostate cancer: a phase II study.

The threefold value of surgery in previously irradiated brain metastases.

Concurrent New Systemic Therapies and Radiation Therapy in Breast Cancer: Current Evidence, Future Challenges, and Expert Practice Recommendations for Low- and Middle-Income Countries.

A phase I dose-escalation/expansion study of fractionated-dose and multiple cycle anti-PSMA-targeted alpha emitter 225Ac-J591 in patients with prostate cancer.

Dosimetry and pharmacokinetics of [²²³Ra]Ra-dichloride alpha therapy in prostate cancer patients with bone metastases.

Preliminary feasibility of pre-treatment F-18-PSMA-1007 PET/CT in dose prediction for Lu-177-PSMA-I&T therapy.

Skeletal muscle radiodensity as an automated survival predictor in men with metastatic castration-resistant prostate cancer undergoing PSMA-targeted radioligand therapy.